Research programme: nitric oxide-donating compounds - NicOx

Drug Profile

Research programme: nitric oxide-donating compounds - NicOx

Alternative Names: HCT 2037; NCX 1236; NCX 226; NCX 429; NCX 6550; NCX 8001; NCX 976

Latest Information Update: 31 Jul 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NicOx
  • Class Nitrates
  • Mechanism of Action Cyclooxygenase inhibitors; Endothelin receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bacterial infections; Cancer; Diabetic retinopathy; Hypertension; Inflammation; Metabolic disorders; Osteoarthritis; Pain; Pulmonary arterial hypertension; Viral infections

Most Recent Events

  • 27 Jul 2012 Discontinued - Preclinical for Inflammation in France (unspecified route)
  • 27 Jul 2012 Discontinued - Preclinical for Pulmonary hypertension in France (unspecified route)
  • 27 Jul 2012 Discontinued for Diabetic retinopathy in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top